CYP2D6 and neoplasm: There remains a need for properly designed trials associating the CYP2D6 phenotype to outcome, as long-term survival in ER+ breast cancer is confounded by many factors such as the tumor subtype [1], menopausal status [26], use of aromatase inhibitors [5], and chemotherapy [27].